natgillin/translations-raw huggingface dataset:
Pharmacokinetics and pharmacodynamics of avatrombopag have not been investigated in patients with severe renal impairment (CrCL < 30 mL/min, Cockcroft-Gault) including patients requiring haemodialysis. 
Farmakokinetika i farmakodinamika avatrombopaga nije ispitana u bolesnika s teškim oštećenjem bubrega (CrCL < 30 ml/min, CockcroftGault), uključujući bolesnike kojima je potrebna hemodijaliza.
Table 3: Drug interactions: Changes in pharmacokinetics of avatrombopag in the presence of co-administered drug 
Tablica 3: Interakcije s lijekovima: Promjene u farmakokinetici avatrombopaga u prisutnosti drugog, istodobno primijenjenog lijeka
Geometric mean ratio [90% CI] of avatrombopag PK with/without co administered drug (No Effect = 1.00) 
Omjer geometrijskih srednjih vrijednosti [90% CI] PK-a avatrombopaga s/bez istodobno primijenjenog lijeka (bez učinka = 1,00)
b Cochran-Mantel-Haenszel Test. c Wilcoxon Rank Sum Test. 
b Cochran-Mantel-Haenszelov test.
In a multiple-dose pharmacokinetic study in healthy volunteers, steady state was reached by day 5 of dosing. 
U farmakokinetičkom ispitivanju višekratnog doziranja u zdravih dobrovoljaca, stanje dinamičke ravnoteže postignuto do 5. dana doziranja.
Doptelet is not recommended in pregnancy and in women who are able to have children and are not using contraception. 
Doptelet se ne preporučuje tijekom trudnoće ili u žena koje mogu zanijeti, a ne koriste kontracepciju.
You may be at higher risk of blood clots as you get older or if: - you have had to stay in bed for a long time - you have cancer - you are taking the contraceptive birth control pill or hormone replacement therapy - you have recently had surgery or been injured 
Rizik od krvnih ugrušaka može rasti kako starite ili ako: ste morali dugo boraviti u krevetu imate rak uzimate kontracepcijsku pilulu ili nadomjesnu hormonsku terapiju ste nedavno operirani ili se ozlijedili ste izrazito prekomjerne tjelesne težine pušite imate uznapredovalu kroničnu bolest jetre.
In two-year carcinogenicity studies in mice and rats, neuroendocrine cell (enterochromaffin-like cell, ECL cell) gastric tumours (carcinoids) occurred in the stomach at high doses. 
U dvogodišnjim ispitivanjima kancerogeničnosti u miševa i štakora pojavili su se želučani tumori neuroendokrinih stanica (stanice nalik na enterokromafine, ECL stanice) (karcinoidi) u trbuhu pri visokim dozama.
Macrogol 3350 (E1521) Titanium dioxide (E171) Iron oxide yellow (E172) 
Makrogol 3350 (E1521) Titanijev dioksid (E171) Željezov oksid, žuti (E172)
Concomitant use of avatrombopag with P-gp inhibitors resulted in alterations in exposure that were not clinically significant. 
Istodobna primjena avatrombopaga s Pgp inhibitorima dovela je do promjena u izloženosti koje nisu bili klinički značajne.
The exposures (AUC) at doses that showed no gastric lesions across the species were 3- to 33-fold higher than the exposures in humans at the maximum recommended human dose (MRHD). 
Izloženosti (AUC) pri dozama koje nisu pokazale želučane lezije u raznih vrsta bile su od 3 do 33 puta veće od izloženosti u ljudi pri maksimalnoj preporučenoj dozi za ljude
Doptelet 20 mg film-coated tablets are pale yellow, round, rounded on the upper and lower side, marked with “AVA” imprinted on one side and “20” on the other. 
Doptelet 20 mg filmom obložene tablete su svijetlo žute, okrugle tablete zaobljene na gornjoj i donjoj strani, s utisnutom oznakom „AVA” na jednoj strani i „20” na drugoj.
60 mg (Three 20 mg tablets) 
60 mg (tri tablete od 20 mg)
Platelet count (x109/L) 
Broj trombocita (x109/L)
Avatrombopag plasma exposure was comparable in patients with chronic liver disease secondary to viral hepatitis (n = 242), non-alcoholic steatohepatitis (n = 45) and alcoholic liver disease (n = 49) in the pivotal Phase 3 studies, and also comparable to that in healthy subjects (n = 391). 
Izloženost avatrombopagu u plazmi je bila usporediva u bolesnika s kroničnom bolešću jetre uzrokovanom virusnim hepatitisom (n = 242), nealkoholnim steatohepatitisom (n = 45) i alkoholnom bolešću jetre (n = 49) u pivotalnim ispitivanjima faze 3, ali također usporediva i s onom u zdravih ispitanika (n = 391).
Do not use this medicine after the expiry date which is stated on the carton and on each blister after ‘EXP'. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i svakom blisteru.
Avatrombopag was present in milk of lactating rats after oral administration of radioactive labeled avatrombopag. 
Avatrombopag je bio prisutan u mlijeku štakora nakon peroralne primjene radioaktivno označenog avatrombopaga.
The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts due to the 5-day treatment duration, and no dose adjustment is recommended. 
Ne očekuje se kako će povećanje izloženosti avatrombopagu imati klinički značajan učinak na broj trombocita jer liječenje traje pet dana, pa se ne preporučuje prilagodba doze.
Two doses should not be taken at one time to make up for a missed dose. 
Ne smije se uzeti dvostruka doza kako bi se nadoknadila propuštena.
Open label, randomised, cross-over replicate design clinical trials were conducted in healthy subjects to assess the effects of high-fat and low-fat food on the bioavailability and pharmacokinetic variability of avatrombopag. 
Otvorena, randomizirana, ukrižena ispitivanja replikativnog dizajna provedena su u zdravih ispitanika kako bi se procijenio učinak hrane s visokim udjelom masnoća i hrane s niskim udjelom masnoća na bioraspoloživost te farmakokinetičku varijabilnost avatrombopaga.
Avatrombopag is not a substrate for OATP1B1, OATP1B3, OCT2, OAT1, and OAT3. 
Avatrombopag nije supstrat za OATP1B1, OATP1B3, OCT2, OAT1 i OAT3.
40 mg (Two 20 mg tablets) 
40 mg (dvije tablete od 20 mg)
Avatrombopag is not renally excreted, therefore no dose adjustment is required in patients with mild or moderate renal impairment. 
Avatrombopag se ne izlučuje putem bubrega, pa nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem bubrega.
Avatrombopag is a substrate for p-glycoprotein (P-gp) mediated transport, although no clinically important differences in platelet count elevations are expected when avatrombopag is co-administered with a strong P-gp inhibitor. 
Avatrombopag je supstrat za transport posredovan p-glikoproteinom (Pgp), iako se ne očekuju klinički značajne razlike u povećanju broja trombocita kada se avatrombopag primjenjuje zajedno sa snažnim inhibitorom Pgp-a.
The plasma concentration-time profiles following the oral administration of avatrombopag were characterised by a short lag time (0.5 - 0.75 hours) with peak exposure at 6 - 8 hours post dose. 
Profili koncentracija-vrijeme u plazmi su za peroralno primjenjen avatrombopag okarakterizirani kratkom odgodom (0,5 - 0,75 sati) i vrhuncem izloženosti 6 - 8 sati nakon doze.
The European Medicines Agency has waived the obligation to submit the results of studies with Doptelet in all subsets of the paediatric population in thrombocytopenia secondary to liver disease (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Doptelet u svim podskupinama pedijatrijske populacije s trombocitopenijom kao posljedicom bolesti jetre (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Avatrombopag did not affect fertility or early embryonic development in male rats at exposures 22-times, or in female rats at exposures 114-times, the AUC observed in patients at the recommended dose of 60 mg once daily. 
Avatrombopag nije utjecao na plodnost ni rani embrionalni razvoj u mužjaka štakora pri 22-strukim vrijednostima izloženosti niti u ženki štakora pri 114-strukim vrijednostima izloženosti (AUC) postignute u bolesnika pri preporučenoj dozi od 60 mg jednom dnevno.
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. 
Doptelet je indiciran za liječenje teške trombocitopenije u odraslih bolesnika s kroničnom bolešću jetre koji će biti podvrgnuti invazivnom postupku.
Should overdose occur or be suspected, Doptelet dosing should be stopped and platelet count should be carefully monitored since avatrombopag increases platelet count in a dose-dependent fashion. 
Ako dođe do predoziranja ili sumnje na predoziranje, uzimanje Dopteleta treba prekinuti, a broj trombocita treba pažljivo pratiti, jer je povećanje broja trombocita ovisno o dozi avatrombopaga.
Keep this medicine out of the sight and reach of children. 
Kako čuvati Doptelet Lijek čuvajte izvan pogleda i dohvata djece.
Patients with Child Pugh class C liver disease, should be evaluated on the day of the procedure for an unexpectedly high increase in platelet count. 
U bolesnika s bolešću jetre stupnja Child Pugh C treba na dan postupka provjeriti prisutnost neočekivano visokog porasta broja trombocita.
In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n = 1/430) with chronic liver disease and thrombocytopenia which was reported 14 days after treatment with Doptelet ended. 
U kliničkim ispitivanjima ADAPT-1 i ADAPT-2 je došlo do pojave 1 događaja tromboze portalne vene u jednog bolesnika (n = 1/430) s kroničnom bolešću jetre i trombocitopenijom, koji je prijavljen 14 dana nakon završetka liječenja Dopteletom.
Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production. 
Avatrombopag se ne natječe s TPO-om u vezivanju na receptor TPO-a i ima aditivan učinak djelovanju TPO-a na proizvodnju trombocita.
Administration with either type of food did not have any clinically important effects on rate (Cmax) or extent (AUC) of avatrombopag exposure. 
Uzimanje s bilo kojom vrstom hrane nije imalo nikakav klinički značajan učinak na stopu (Cmax) ili opseg (AUC)
No dosage adjustment is necessary for patients with mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment. 
Nije potrebna prilagodba doze u bolesnika s blagim (Child-Pugh A) do umjerenim (Child-Pugh B)
The predominant route of avatrombopag excretion is via faeces. 
Dominantan put izlučivanja avatrombopaga je putem stolice.
Avatrombopag is an orally active, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. 
Avatrombopag je peroralno aktivan agonist receptora trombopoetina (TPO), male molekularne mase, koji potiče proliferaciju i diferencijaciju megakariocita iz progenitorskih stanica koštane srži i koji uzrokuje povećanu proizvodnju trombocita.
The safety of avatrombopag was evaluated in two randomised, double-blind, placebo-controlled trials, Study 1 and Study 2, in which 430 patients with chronic liver disease and thrombocytopenia received either avatrombopag (n = 274) or placebo (n = 156), and had 1 post-dose safety assessment. 
Sigurnost avatrombopaga je procijenjena u dva randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja, Ispitivanju 1 i Ispitivanju 2, u kojima je 430 bolesnika s kroničnom bolešću jetre i trombocitopenijom uzimalo ili avatrombopag (n = 274) ili placebo (n = 156) te imalo 1 sigurnosnu procjenu nakon uzimanja.
• blood clot in the portal vein (blood vessel that carries blood to the liver from the intestines) 
• krvni ugrušak u portalnoj veni (krvna žila koja prenosi krv od crijeva do jetre) koji može dovesti do pojave bolova ili oticanja u gornjem dijelu trbuha
Interferon preparations have been known to reduce platelet counts, therefore, this should be considered when co-administering avatrombopag with interferon preparations. 
Poznato je da pripravci interferona smanjuju broj trombocita, pa to treba uzeti u obzir kod istodobne primjene avatrombopaga s pripravcima interferona.
However, these patients should be evaluated on the day of the procedure for an unexpectedly high increase in platelet count (see section 4.2 and 5.2). 
Međutim, u tih bolesnika na dan postupka treba provjeriti je li se pojavio neočekivano visok porast broja trombocita (vidjeti dio 4.2 i 5.2).
Avatrombopag should only be used in such patients if the expected benefit outweighs the expected risks (see sections 4.2 and 5.2). 
Terapiju avatrombopagom u takvih bolesnika treba započeti samo ako je očekivana korist veća od očekivanih rizika (vidjeti dio 4.2 i 5.2).
The most important treatment-emergent adverse reaction associated with avatrombopag was portal vein thrombosis. 
Najvažnija nuspojava nastala kod liječenja, povezana s avatrombopagom, bila je tromboza portalne vene.
Patients in the low baseline platelet count cohort received 60 mg avatrombopag or matching placebo once daily for 5 days, and patients in the high baseline platelet count cohort received 40 mg avatrombopag or matching placebo once daily for 5 days. 
Bolesnici s niskom početnom vrijednošću broja trombocita su primali 60 mg avatrombopaga ili odgovarajuću dozu placeba jednom dnevno tijekom 5 dana, a bolesnici s visokom početnom vrijednošću broja trombocita 40 mg avatrombopaga ili odgovarajuću dozu placeba jednom dnevno tijekom 5 dana.
Portal vein thrombosis has been reported at an increased frequency in patients with chronic liver disease who had platelet counts > 200 x 109/L receiving a thrombopoietin receptor agonist (see section 4.8). 
Tromboza portalne veni je prijavljena s većom učestalosti u bolesnika s kroničnom bolešću jetre čiji je broj trombocita bio > 200 x 109/L, a koji su primali agoniste receptora trombopoetina (vidjeti dio 4.8).
In these species, avatrombopag was associated with histopathologic changes in the fundic mucosa of the glandular stomach, characterised by degeneration of the glandular epithelium with a decrease in matured parietal cells. 
U ovih vrsta je avatrombopag bio povezan s histopatološkim promjenama u sluznici fundusa žljezdanog želuca, koje karakteriziraju degeneracija žljezdanog epitela sa smanjenjem broja zrelih parijetalnih stanica.
If any of the above applies to you, or you are not sure, talk to your doctor or pharmacist before taking Doptelet. 
Ako se bilo što od navedenog odnosi na Vas ili ako niste sigurni, prije uzimanja Dopteleta razgovarajte sa svojim liječnikom ili ljekarnikom.
In Study 1, a total of 231 patients were randomised; 149 patients to the avatrombopag group and 82 patients to the placebo group. 
U Ispitivanju 1 je randomiziran ukupno 231 bolesnik, od čega 149 bolesnika u skupinu koja je uzimala avatrombopag, a 82 bolesnika u placebo skupinu.
- The active substance is avatrombopag. 
Djelatna tvar je avatrombopag.
Avatrombopag therapy should only be initiated in patients with severe hepatic impairment if the expected benefit outweighs the expected risks (see sections 4.4 and 5.2). 
Terapiju avatrombopagom u bolesnika s teškim oštećenjem jetre smije se započeti samo ako je očekivana korist veća od očekivanih rizika (vidjeti dio 4.4 i 5.2).
Doptelet contains an active substance called avatrombopag. 
Doptelet sadrži djelatnu tvar pod nazivom avatrombopag.
The apparent volume of distribution of avatrombopag in patients with thrombocytopenia and chronic liver disease based on population pharmacokinetic analysis is approximately 180 L, suggesting that avatrombopag is extensively distributed. 
Prividni volumen distribucije avatrombopaga u bolesnika s trombocitopenijom i kroničnom bolešću jetre temeljen na farmakokinetičkoj analizi populacije je približno 180 L, što upućuje na to da se avatrombopag opsežno distribuira.
Doptelet is not recommended during pregnancy and in women of childbearing potential not using contraception. 
Ne preporučuje se primjena Dopteleta tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
Concomitant use of avatrombopag with strong CYP3A4/5 or CYP2C9 inhibitors increases avatrombopag exposure. 
Istodobna primjena avatrombopaga sa snažnim inhibitorima CYP3A4/5 ili CYP2C9 povećava izloženost avatrombopagu.
Tablet core: lactose monohydrate (see section 2 “Doptelet contains lactose”); microcrystalline cellulose [E460(i)]; crospovidone type B [E1202]; silica, colloidal anhydrous [E551]; magnesium stearate [E470b]. 
Jezgra tablete: laktoza hidrat (vidjeti dio 2. „Doptelet sadrži laktozu”), mikrokristalična celuloza [E460(i)]; krospovidon vrsta B [E1202]; silicijev dioksid, koloidni, bezvodni [E551]; magnezijev stearat [E470b].
Film coating: poly(vinyl alcohol) [E1203]; talc [E553b]; macrogol 3350 [E1521]; titanium dioxide [E171]; iron oxide yellow [E172]. 
Film ovojnica: poli(vinilni alkohol) [E1203]; talk [E553b]; makrogol 3350 [E1521]; titanijev dioksid [E171]; željezov oksid, žuti [E172].
Table 1 Daily dose recommendation for avatrombopag 
Tablica 1 Dnevno preporučena doza avatrombopaga
In Study 2, a total of 204 patients were randomised; 128 patients to the avatrombopag treatment group and 76 patients to the placebo treatment group. 
U Ispitivanju 2 je randomizirano ukupno 204 bolesnika, od čega 128 bolesnika u skupinu koja je uzimala avatrombopag, a 76 bolesnika u placebo skupinu.
Population pharmacokinetic analysis of avatrombopag plasma concentrations from clinical studies with healthy subjects and patients with thrombocytopenia due to chronic liver disease, that included 11% (84/787) of the study population ≥ 65 years of age, suggested that avatrombopag exposures are not affected by age (see section 4.2). 
Starije osobe Populacijska farmakokinetička analiza koncentracije avatrombopaga u plazmi u kliničkim ispitivanjima u zdravih ispitanika i bolesnika s trombocitopenijom nastalom zbog kronične bolesti jetre, što je uključivalo 11% (84/787) ispitivane populacije ≥ 65 godina, upućuje na to kako na izlaganje avatrombopagu ne utječe dob (vidi dio 4.2).
Concomitant use of strong CYP3A4/5 or CYP2C9 inducers reduces avatrombopag exposure, and may result in a decreased effect on platelet counts; however, no dose adjustment is recommended (see section 5.2). 
Snažni induktori CYP3A4/5 ili CYP2C9 Istodobna primjena snažnih CYP3A4/5 ili CYP2C9 induktora smanjuje izloženost avatrombopagu i može dovesti do smanjenja učinka na broja trombocita; no ne preporučuje se prilagodba doze (vidjeti dio 5.2).
Pale yellow, round biconvex film-coated 7.6 mm tablet debossed with “AVA” on one side and “20” on the other. 
Svijetložuta, okrugla, bikonveksna filmom obložena tableta veličine 7,6 mm s utisnutom oznakom „AVA” s jedne i „20” s druge strane.
There are no or limited amount of data from the use of avatrombopag in pregnant women. 
Nema podataka ili su podaci o primjeni avatrombopaga u trudnica ograničeni.
Co. Dublin 
Dublin 2
If you have any questions on the use of this medicine, ask your doctor or pharmacist. 
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se liječniku ili ljekarniku.
Obtain a platelet count prior to the administration of Doptelet therapy and on the day of a procedure to ensure an adequate increase in platelet count, and no unexpectedly high increase in platelet count in the patient populations specified in sections 4.4 and 4.5. 
Prije primjene terapije Dopteletom kao i na sam dan invazivnog postupka potrebno je provjeriti broj trombocita kako biste osigurali da je porast trombocita odgovarajući, i da ne postoji neočekivano visok porast razine trombocita u populaciji bolesnika navedenoj u dijelu 4.4 i 4.5.
Doptelet should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts. 
Doptelet se ne smije primjenjivati u bolesnika s kroničnom bolešću jetre kao pokušaj normaliziranja broja trombocita.
Dova Pharmaceuticals Ireland, Limited 
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Dova Pharmaceuticals Ireland, Limited
Avatrombopag inhibits organic anion transporter (OAT) 1 and 3 and breast cancer resistance protein (BCRP) but not organic anion transporter polypeptide (OATP) 1B1 and 1B3, and organic cation transporter (OCT) 2 in vitro. 
Avatrombopag inhibira OAT (engl. organic anion transporter) 1 i 3 te BCRP (engl.,breast cancer resistance protein) ali ne i OATP (engl. organic anion transporter polypeptide) 1B1 i 1B3 ni OCT
Avatrombopag was not mutagenic in an in vitro bacterial reverse mutation (AMES) assay or clastogenic in an in vitro human lymphocyte chromosomal aberrations assay or in an in vivo rat bone marrow micronucleus assay. 
Avatrombopag nije bio mutagen u in vitro testu bakterijske reverzne mutacije (AMES), niti klastogen u in vitro testu kromosomskih aberacija ljudskih limfocita niti u in vivo mikronukleus testu koštane srži štakora.
A measured increase in platelet counts was observed in both avatrombopag treatment groups over time beginning on Day 4 post-dose, which peaked on Day 10-13 and then returned to near baseline values by Day 35 (Figure 1); mean platelet count remained greater than or equal to 50 x 109/L on Day 17 (Visit 5). 
počevši od 4. dana nakon doziranja, koje je dosegnulo vrhunac na 10.-13. dan, a zatim se vratilo na vrijednosti slične početnim vrijednostima na 35. dan (Slika 1); srednja vrijednost broja trombocita je ostala veća od ili jednaka 50 x 109/L na 17. dan (Posjet 5).
Table 2: Efficacy results by baseline platelet count cohort and treatment group - Study 1 and Study 2 
Tablica 2: Rezultati djelotvornosti za kohorte prema početnoj vrijednosti broja trombocita i terapijske skupine - Ispitivanje 1 i Ispitivanje 2
Co-administration of avatrombopag with either a high-fat or low-fat meal did not result in clinically important changes in rate or extent of absorption of avatrombopag. 
Istovremena primjena avatrombopaga i hrane s visokim ili hrane s niskim udjelom masnoća nije dovela do klinički značajnih promjena u stopi ili opsegu apsorpcije avatrombopaga.
Musculoskeletal & connective tissue disorders 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva
Dova Pharmaceuticals Ireland, Limited 6th Floor, 2 Grand Canal Square Dublin 2 
Nositelj odobrenja za stavljanje lijeka u promet Dova Pharmaceuticals Ireland, Limited 6th Floor, 2 Grand Canal Square Dublin 2
10 film-coated tablets 15 film-coated tablets 
15 filmom obloženih tableta
No clinically important difference in avatrombopag exposures were observed between patients with Child-Turcotte-Pugh Scores (Range = 5 to 12) or MELD scores (Range = 4 to 23) and healthy subjects. 
Nisu uočene klinički značajne razlike u izloženosti avatrombopagu u bolesnika s rezultatima prema ChildTurcottePugh klasifikaciji (raspon = od 5 do 12) i MELD rezultatima (raspon = od 4 do 23) nasuprot zdravim ispitanicima.
However, administration of avatrombopag with both a high- and low-fat meal reduced inter-subject and intra-subject pharmacokinetic variability of avatrombopag by approximately 50%. 
No istovremena primjena avatrombopaga i hrane bilo s visokim ili niskim udjelom masnoća je smanjila farmakokinetičku varijabilnost avatrombopaga interindividualno i intraindividualno za približno 50%.
High baseline platelet count (≥ 40 to < 50 x 109/L) 
Skupina s visokom početnom vrijednosti broja trombocita (≥ 40 do < 50 x 109/L)
Each blister contains either 10 or 15 tablets. 
10 ili 15 tableta.
CYP3A4/5 and CYP2C9 inhibitors 
Inhibitori CYP3A4/5 i CYP2C9
If you are not sure, talk to your doctor or pharmacist before taking Doptelet. 
Ako niste sigurni, prije uzimanja Dopteleta razgovarajte sa svojim liječnikom ili ljekarnikom.
If you are breast-feeding, ask your doctor or pharmacist for advice before taking Doptelet. 
Ako dojite, zatražite savjet svog liječnika ili ljekarnika prije uzimanja Dopteleta.
Low baseline platelet count cohort (< 40 x 109/L) 
Kohorta s niskom početnom vrijednošću broja trombocita (< 40 x 109/L)
Doptelet 20 mg film-coated tablets 
Doptelet 20 mg filmom obložene tablete
60 mg (3 tablets) every day for 5 days in a row. 
Uobičajena preporučena doza je 40 mg (2 tablete) ili 60 mg (3 tablete) svakog dana, 5 dana za redom.